Therapeutic Targets and Biomarkers of Tumor Immunotherapy: Response Versus Non-Response

Immune checkpoint blocking therapy, represented by PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, has shown encouraging therapeutic effects in the treatment of various malignant tumors, such as non-small cell lung cancer and melanoma.